Technical analysis of Seres Therapeutics, Inc. (MCRB): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI).
Price Performance
| 1 month | -3.00% |
| 3 months | -36.31% |
| Year-to-date | -71.71% |
| 1 year | -76.09% |
| 3 years | -92.35% |
| 5 years | -97.04% |
52-Week Range
| 52-week High | $29.98 |
| 52-week Low | $4.18 |
| Avg Volume (90d) | 77K |
Technical Indicators
| SMA 50 | $5.07 |
| SMA 200 | $9.21 |
| Beta | 0.26 |
| 30-day Volatility (annualised) | 68.7% |
| Price vs SMA 50 | -17.0% |
| Price vs SMA 200 | -54.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $16.10 | |
| 2025-11 | $17.99 | +11.7% |
| 2025-12 | $14.88 | -17.3% |
| 2026-01 | $14.92 | +0.3% |
| 2026-02 | $8.74 | -41.4% |
| 2026-03 | $8.87 | +1.5% |
| 2026-04 | $7.37 | -16.9% |
| 2026-05 | $7.32 | -0.7% |
| 2026-06 | $7.89 | +7.8% |
| 2026-07 | $4.83 | -38.8% |
| 2026-08 | $4.91 | +1.7% |
| 2026-09 | $4.21 | -14.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $4.21 |
| Market Cap | $41M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.32 |
| EV / EBITDA | -2.17 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 1.64 |
| Current Ratio | 2.11 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -10.99 |